Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dupixent
Pharma
Regeneron sees more regulatory issues, sales declines for Eylea
As regulatory delays continue to plague Regeneron's Eylea, quarterly sales for the treatment have dropped below $1B for the first time since 2018.
Kevin Dunleavy
Apr 29, 2026 12:05pm
Sanofi has 'vigorous defense planned' for Dupixent patent cliff
Apr 23, 2026 1:35pm
Lilly's Ebglyss scores eczema trial win in children
Mar 16, 2026 10:50am
Galderma doubles Nemluvio peak sales outlook to $4B-plus
Mar 5, 2026 11:20am
Regeneron faces category headwinds for eye disease drug Eylea
Jan 30, 2026 11:41am
Sanofi shrugs off policy tumult as it predicts vaccine sales dip
Jan 29, 2026 11:42am
